Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

To clarify the efficacy and safety of protein A immunoadsorption therapy for acute exacerbations of neuromyelitis optica spectrum disorders(NMOSD), we designed a multicenter, open-label, superiority randomized controlled clinical trial, planning to enroll 144 patients with NMOSD. We plan to treat patients with acute NMOSD using protein A immunoadsorption combined with high-dose intravenous methylprednisolone, and compare this with treatment using high-dose intravenous methylprednisolone alone. The aim is to observe the impact and safety of protein A immunoadsorption on the treatment efficacy for these patients experiencing acute exacerbations of NMOSD, ultimately providing more comprehensive clinical evidence to support treatment protocols for the acute phase of NMOSD.

NCT Number	NCT06763848
Lead Sponsor	Third Affiliated Hospital, Sun Yat-Sen University Collaborators: Second Affiliated Hospital of Guangzhou Medical University, Guangdong 999 Brain Hospital, Second Xiangya Hospital of Central South University, Beijing Friendship Hospital
Conditions	Neuromyelitis Optica Spectrum Disorders
Enrollment	144 participants
Start Date	2025-04-25
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-30